These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 6366241

  • 1. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
    Coker SJ, Parratt JR.
    J Mol Cell Cardiol; 1984 Jan; 16(1):43-52. PubMed ID: 6366241
    [Abstract] [Full Text] [Related]

  • 2. The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.
    Fiedler VB, Mardin M, Perzborn E, Grützmann R.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):267-74. PubMed ID: 3841382
    [Abstract] [Full Text] [Related]

  • 3. Nifedipine reduces arrhythmias but does not alter prostanoid release during coronary artery occlusion and reperfusion in anaesthetised greyhounds.
    Coker SJ, Parratt JR.
    J Cardiovasc Pharmacol; 1983 Nov; 5(3):406-17. PubMed ID: 6191139
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease.
    Roy L, Mehta J, Mehta P.
    Am Heart J; 1985 May; 109(5 Pt 1):1026-31. PubMed ID: 3158183
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prostacyclin--antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK36374 during coronary artery occlusion and reperfusion in anaesthetised greyhounds.
    Coker SJ, Parratt JR.
    J Cardiovasc Pharmacol; 1983 May; 5(4):557-67. PubMed ID: 6193351
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Arachidonic acid cascade and the generation of ischemia- and reperfusion-induced ventricular arrhythmias.
    Parratt JR, Coker SJ.
    J Cardiovasc Pharmacol; 1985 May; 7 Suppl 5():S65-70. PubMed ID: 2410739
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats.
    Feuerstein G, Bayorh MA, Stull R, Goldstein DS, Zerbe RL, Ramwell PW, Faden AI.
    Circ Shock; 1985 May; 17(3):223-32. PubMed ID: 3841032
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Failure of cyclo-oxygenase inhibition to protect against arrhythmias induced by ischaemia and reperfusion: implications for the role of prostaglandins as endogenous myocardial protective substances.
    Wainwright CL, Parratt JR.
    Cardiovasc Res; 1991 Feb; 25(2):93-100. PubMed ID: 1742769
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575).
    Strasser T, Fischer S, Weber PC.
    Biochem Pharmacol; 1985 Jun 01; 34(11):1891-4. PubMed ID: 2988560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.